Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab.

Liver Cancer · 2025 · PMC12360742 · PMID 40831890

Europe PMC DOI

hedged sentence

0.2570

closest p · 5.1× alpha

0.2570

boldest claim

The sentences

showed a trendp = 0.257not close (p > 0.1)

5.3 months, p = 0.044) and showed a trend toward shorter OS (5.7 vs. 12.3 months, p = 0.257) compared to those with AFP <400 ng/mL ( Fig. 3 c, d).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.